---
figid: PMC3303935__nihms335230f1
figlink: /pmc/articles/PMC3303935/figure/F1/
number: Figure 1
caption: 'Numerous TLRs are expressed and activated in astrocytes including TLRs 2,
  3, 4, 5, 7, and 9. Several ligands have been found to activate certain TLRs in astrocytes
  including, but not limited to: lipoteichoic acid (LTA) (TLR2), soluble CD14 (TLR2),
  peptidoglycan (PGN) (TLR2, TLR4 TLR9), flagellin (TLR2, TLR4, TLR9), bacterial CpGs
  (TLR4, TLR5), high mobility group box-1 (HMGB1) (TLR2, TLR4), double-stranded RNA
  (dsRNA) (TLR3), lipopolysaccharide (LPS) (TLR4, TLR9) and Imiquimod (TLR7). Upon
  astrocytic TLR activation, numerous mediators are released, resulting in proinflammation.
  Such mediators include the proinflammatory cytokines: interleukin-6 (IL-6), interleukin-1alpha
  (IL-1α), tumor necrosis factor-alpha (TNF-α), IL-5, IL-13, IL-12p40, in addition
  to numerous proinflammatory mediators and chemokines: monocyte chemotactic protein-1
  (MCP-1), reactive oxygen species (ROS), RANTES, interferon-beta (IFN-β), CXCL10,
  CCL5, inducible nitric oxide synthase (iNOS) and nitric oxide (NO). All TLRs, are
  known to signal via the MyD88 pathway excluding TLR3 which utilises the Toll/IL1
  receptor (TIR) adaptor protein TRIF (Toll-receptor-associated activator of interferon),
  and TLR4 which can signal via both MyD88 and TRIF. Upon astrocytic TLR activation
  however, certain signalling components have been shown to be upregulated. TLR2 activation
  in astrocytes for example, has been demonstrated to utilise the co-receptor CD14.
  Furthermore, upon TLR4 activation, the TRIF-dependent pathway of TLR4 signalling
  has been shown to be inactive in astrocytes and utilizes the co-receptors MD-2 and
  CD14. (; ; ; ; ; ; ; ).'
pmcid: PMC3303935
papertitle: Toll-Like Receptors in Chronic Pain.
reftext: Lauren Nicotra, et al. Exp Neurol. ;234(2):316-329.
pmc_ranked_result_index: '158492'
pathway_score: 0.8731501
filename: nihms335230f1.jpg
figtitle: Toll-Like Receptors in Chronic Pain
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3303935__nihms335230f1.html
  '@type': Dataset
  description: 'Numerous TLRs are expressed and activated in astrocytes including
    TLRs 2, 3, 4, 5, 7, and 9. Several ligands have been found to activate certain
    TLRs in astrocytes including, but not limited to: lipoteichoic acid (LTA) (TLR2),
    soluble CD14 (TLR2), peptidoglycan (PGN) (TLR2, TLR4 TLR9), flagellin (TLR2, TLR4,
    TLR9), bacterial CpGs (TLR4, TLR5), high mobility group box-1 (HMGB1) (TLR2, TLR4),
    double-stranded RNA (dsRNA) (TLR3), lipopolysaccharide (LPS) (TLR4, TLR9) and
    Imiquimod (TLR7). Upon astrocytic TLR activation, numerous mediators are released,
    resulting in proinflammation. Such mediators include the proinflammatory cytokines:
    interleukin-6 (IL-6), interleukin-1alpha (IL-1α), tumor necrosis factor-alpha
    (TNF-α), IL-5, IL-13, IL-12p40, in addition to numerous proinflammatory mediators
    and chemokines: monocyte chemotactic protein-1 (MCP-1), reactive oxygen species
    (ROS), RANTES, interferon-beta (IFN-β), CXCL10, CCL5, inducible nitric oxide synthase
    (iNOS) and nitric oxide (NO). All TLRs, are known to signal via the MyD88 pathway
    excluding TLR3 which utilises the Toll/IL1 receptor (TIR) adaptor protein TRIF
    (Toll-receptor-associated activator of interferon), and TLR4 which can signal
    via both MyD88 and TRIF. Upon astrocytic TLR activation however, certain signalling
    components have been shown to be upregulated. TLR2 activation in astrocytes for
    example, has been demonstrated to utilise the co-receptor CD14. Furthermore, upon
    TLR4 activation, the TRIF-dependent pathway of TLR4 signalling has been shown
    to be inactive in astrocytes and utilizes the co-receptors MD-2 and CD14. (; ;
    ; ; ; ; ; ).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MYD88
  - MAPK10
  - IRF6
  - LTA
  - NFKB2
  - CCL2
  - NFKB1
  - IL6
  - TNF
  - REL
  - TLR2
  - CXCL10
  - MAPK1
  - CCL5
  - IL1B
  - MAPK8
  - TLR3
  - IL1A
  - IRF3
  - AKT1
  - MAPK9
  - RELB
  - HMGB1
  - CCL3
  - RELA
  - MAPK3
  - IL13
  - AKT3
  - IFNB1
  - IL5
  - TLR5
  - CD14
  - CXCL8
  - AKT2
  - TLR7
  - TLR9
  - TLR4
genes:
- word: MyD88
  symbol: MYD88
  source: hgnc_symbol
  hgnc_symbol: MYD88
  entrez: '4615'
- word: JNK
  symbol: JNK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: LPS,
  symbol: LPS
  source: hgnc_prev_symbol
  hgnc_symbol: IRF6
  entrez: '3664'
- word: LTA,SolubleCD14,
  symbol: LTA
  source: hgnc_symbol
  hgnc_symbol: LTA
  entrez: '4049'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB2
  entrez: '4791'
- word: MCP-1,
  symbol: MCP-1
  source: hgnc_alias_symbol
  hgnc_symbol: CCL2
  entrez: '6347'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: IL-6,IL-1a,TNF-a,
  symbol: IL-6
  source: hgnc_alias_symbol
  hgnc_symbol: IL6
  entrez: '3569'
- word: IL-6,IL-1a,TNF-a,
  symbol: TNF-alpha
  source: hgnc_alias_symbol
  hgnc_symbol: TNF
  entrez: '7124'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: REL
  entrez: '5966'
- word: TLR2
  symbol: TLR2
  source: hgnc_symbol
  hgnc_symbol: TLR2
  entrez: '7097'
- word: RANTES,CCL3,CXCL10,
  symbol: CXCL10
  source: hgnc_symbol
  hgnc_symbol: CXCL10
  entrez: '3627'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: RANTES,IL-1a,IL-1B,NO,
  symbol: RANTES
  source: hgnc_alias_symbol
  hgnc_symbol: CCL5
  entrez: '6352'
- word: IL-1B,
  symbol: IL-1B
  source: hgnc_alias_symbol
  hgnc_symbol: IL1B
  entrez: '3553'
- word: JNK
  symbol: JNK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: TLR3
  symbol: TLR3
  source: hgnc_symbol
  hgnc_symbol: TLR3
  entrez: '7098'
- word: IL-1a,
  symbol: IL-1A
  source: hgnc_alias_symbol
  hgnc_symbol: IL1A
  entrez: '3552'
- word: IRF3
  symbol: IRF3
  source: hgnc_symbol
  hgnc_symbol: IRF3
  entrez: '3661'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: JNK
  symbol: JNK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELB
  entrez: '5971'
- word: HMGB1
  symbol: HMGB1
  source: hgnc_symbol
  hgnc_symbol: HMGB1
  entrez: '3146'
- word: IFN-B,INOS,CCL3,CCL5
  symbol: CCL3
  source: hgnc_symbol
  hgnc_symbol: CCL3
  entrez: '6348'
- word: NFKB
  symbol: NFKB
  source: bioentities_symbol
  hgnc_symbol: RELA
  entrez: '5970'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: IL-13
  symbol: IL-13
  source: hgnc_alias_symbol
  hgnc_symbol: IL13
  entrez: '3596'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: CCL5
  symbol: CCL5
  source: hgnc_symbol
  hgnc_symbol: CCL5
  entrez: '6352'
- word: IFN-B,
  symbol: IFNB
  source: bioentities_symbol
  hgnc_symbol: IFNB1
  entrez: '3456'
- word: IL-5,
  symbol: IL-5
  source: hgnc_alias_symbol
  hgnc_symbol: IL5
  entrez: '3567'
- word: TLR5
  symbol: TLR5
  source: hgnc_symbol
  hgnc_symbol: TLR5
  entrez: '7100'
- word: CD14,
  symbol: CD14
  source: hgnc_symbol
  hgnc_symbol: CD14
  entrez: '929'
- word: CXCL8,
  symbol: CXCL8
  source: hgnc_symbol
  hgnc_symbol: CXCL8
  entrez: '3576'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: TLR7
  symbol: TLR7
  source: hgnc_symbol
  hgnc_symbol: TLR7
  entrez: '51284'
- word: TLR9
  symbol: TLR9
  source: hgnc_symbol
  hgnc_symbol: TLR9
  entrez: '54106'
- word: TLR4
  symbol: TLR4
  source: hgnc_symbol
  hgnc_symbol: TLR4
  entrez: '7099'
chemicals: []
diseases: []
---
